59000EGP
- Active ingredient
- alpelisib
- Strength
- 150mg
- Form
- tablet
- Manufacturer
- novartis > novartis pharma scientific office
- Route
- oral.solid
Uses
Used with fulvestrant for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after progression on endocrine therapy.
Do not use if
Severe hypersensitivity to alpelisib or any component of the formulation.
Side effects
Common adverse effects include hyperglycemia, diarrhea, rash, nausea, fatigue, and decreased appetite. Severe hypersensitivity and skin reactions may occur.
Warnings
Monitor for hyperglycemia, severe skin reactions, pneumonitis, and severe diarrhea.
How it works
Selective PI3K-alpha inhibitor that blocks abnormal signaling pathways involved in tumor growth.
Storage
Store at room temperature in the original package.
